

Gilles Boschetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9115355/publications.pdf>

Version: 2024-02-01

63
papers

2,747
citations

236833

25
h-index

189801

50
g-index

63
all docs

63
docs citations

63
times ranked

4468
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. <i>Digestive and Liver Disease</i> , 2022, 54, 309-315.	0.4	10
2	Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort. <i>Journal of Crohn's and Colitis</i> , 2022, , .	0.6	3
3	No Difference of Adalimumab Pharmacokinetics When Dosed at 40mg Every Week or 80mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2744-2749.	1.1	6
4	Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4429-4435.	1.1	8
5	Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1289-1299.	1.9	30
6	Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	5
7	Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1190-1200.	1.9	11
8	Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive <i>E. coli</i> in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 1007-1018.	1.6	11
9	Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1084-1093.	0.2	40
10	Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. <i>Gut</i> , 2020, 69, 1206-1212.	6.1	92
11	Infliximab induces clinical resolution of sacroiliitis that coincides with increased circulating FOXP3+ T cells in a patient with IPEX syndrome. <i>Joint Bone Spine</i> , 2020, 87, 483-486.	0.8	4
12	Zebrafish modeling of intestinal injury, bacterial exposures, and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	30
13	Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. <i>Cell</i> , 2019, 178, 1493-1508.e20.	13.5	519
14	TRIM33 deficiency in monocytes and macrophages impairs resolution of colonic inflammation. <i>EBioMedicine</i> , 2019, 44, 60-70.	2.7	10
15	Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2610-2612.	2.4	34
16	IBD-INFO Questionnaire: A Multicenter French Up-to-Date Survey of Patient Knowledge in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 943-952.	0.9	14
17	P045 HIGH DIMENSIONAL IMMUNE PHENOTYPING AND TRANSCRIPTIONAL ANALYSES REVEAL ROBUST RECOVERY OF VIABLE HUMAN IMMUNE AND EPITHELIAL CELLS FROM CRYOPRESERVED INTESTINAL TISSUE. <i>Gastroenterology</i> , 2018, 154, S23-S24.	0.6	0
18	Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2078-2085.	0.9	30

#	ARTICLE	IF	CITATIONS
19	Intestinal dendritic cell licensing through Toll-like receptor 4 is required for oral tolerance in allergic contact dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 163-170.	1.5	24
20	Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions. <i>Digestive Diseases</i> , 2018, 36, 417-426.	0.8	3
21	High-dimensional immune phenotyping and transcriptional analyses reveal robust recovery of viable human immune and epithelial cells from frozen gastrointestinal tissue. <i>Mucosal Immunology</i> , 2018, 11, 1684-1693.	2.7	38
22	Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1089-1096.	0.6	15
23	An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. <i>Journal of Geriatric Oncology</i> , 2018, 9, 373-381.	0.5	9
24	A Perioperative Clinical Pathway Can Dramatically Reduce Failure-to-rescue Rates After Cytoreductive Surgery for Peritoneal Carcinomatosis. <i>Annals of Surgery</i> , 2017, 265, 806-813.	2.1	38
25	Gut Inflammation in Mice Triggers Proliferation and Function of Mucosal Foxp3+Regulatory T Cells but Impairs Their Conversion from CD4+T Cells. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 105-117.	0.6	24
26	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 930-935.	0.6	34
27	Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 142-149.	1.9	104
28	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <i>American Journal of Gastroenterology</i> , 2017, 112, 337-345.	0.2	138
29	Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2048-2053.	0.9	36
30	Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 126-132.	0.9	26
31	Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. <i>Digestive and Liver Disease</i> , 2017, 49, 11-16.	0.4	23
32	Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1750-1757.e3.	2.4	102
33	Plasmacytoid dendritic cells are dispensable for noninfectious intestinal IgA responses in vivo. <i>European Journal of Immunology</i> , 2016, 46, 354-359.	1.6	8
34	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1593-1601.e2.	2.4	168
35	Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 727-730.	0.6	1
36	Mouse and Human Liver Contain Immunoglobulin A-Secreting Cells Originating From Peyer's Patches and Directed Against Intestinal Antigens. <i>Gastroenterology</i> , 2016, 151, 311-323.	0.6	65

#	ARTICLE	IF	CITATIONS
37	Costs of Crohn's Disease According to Severity States in France. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2924-2932.	0.9	6
38	Enrichment of Circulating and Mucosal Cytotoxic CD8 ⁺ T Cells Is Associated with Postoperative Endoscopic Recurrence in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 338-345.	0.6	25
39	Facteurs psychosociaux et risque de rechute au cours de la maladie de Crohn. <i>Annales Medico-Psychologiques</i> , 2016, 174, 461-467.	0.2	2
40	Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 865-872.	0.2	114
41	Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 445-451.	0.6	37
42	Abdominal necrotic abscess from colonic fistula treated endoscopically. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1026-1027.	0.5	0
43	GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. <i>BMC Cancer</i> , 2015, 15, 47.	1.1	29
44	Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 331-336.	0.9	67
45	Response to Dai et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 1242.	0.2	0
46	Endoscopic and histologic characteristics of serrated lesions. <i>World Journal of Gastroenterology</i> , 2015, 21, 2896.	1.4	14
47	Management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with colorectal cancer (CC): An interim analysis of an ongoing French national observational study (The OncoBOS study).. <i>Journal of Clinical Oncology</i> , 2015, 33, 742-742.	0.8	1
48	Management of chemotherapy-induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with pancreatic cancer (PC): An interim analysis of an ongoing French national observational study (The OncoBOS study).. <i>Journal of Clinical Oncology</i> , 2015, 33, 479-479.	0.8	0
49	Overview of French Routine Clinical Practice for the Management of Chemotherapy-Induced Anemia (CIA) with Biosimilar Epoetin Alfa in 563 Patients with Lymphoid Malignancies: A National Observational Study (The OncoBOS study). <i>Blood</i> , 2015, 126, 3342-3342.	0.6	1
50	GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. <i>BMC Cancer</i> , 2014, 14, 183.	1.1	163
51	Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 875-880.	0.4	21
52	Pathological Response to Neoadjuvant Chemotherapy: A New Prognosis Tool for the Curative Management of Peritoneal Colorectal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2014, 21, 2608-2614.	0.7	116
53	Su1281 Serrated Polyps in Patients With Inflammatory Bowel Disease: Endoscopic Characteristics Different From Serrated Polyps in the General Population. <i>Gastroenterology</i> , 2014, 146, S-424.	0.6	2
54	Human Herpesvirus 8-Associated Colorectal Kaposi's Sarcoma Occurring in a Drug-induced Immunocompromised Patient with Refractory Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E12-E15.	0.9	14

#	ARTICLE	IF	CITATIONS
55	Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1043-1052.	0.9	89
56	Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. <i>Future Oncology</i> , 2012, 8, 751-756.	1.1	23
57	Yield of Neoplasia by Confocal Laser Endomicroscopy in the Chronic Atrophic Gastritis. <i>Gastroenterology</i> , 2011, 140, S-748-S-749.	0.6	1
58	Therapy with anti-TNF α antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 160-170.	0.9	93
59	Blockade of LTB4/BLT1 pathway improves CD8+ T-cell-mediated colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 279-288.	0.9	9
60	Identification of <i>Mycobacterium cosmeticum</i> sp. as a novel colitogenic infectious agent in a nonimmunocompromised patient. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E128-E130.	0.9	9
61	Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1015-1018.	0.8	12
62	A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. <i>American Journal of Gastroenterology</i> , 2010, 105, 2617-2625.	0.2	164
63	CD4+ T Cells and <i>Lactobacillus casei</i> Control Relapsing Colitis Mediated by CD8+ T Cells. <i>Journal of Immunology</i> , 2009, 183, 5477-5486.	0.4	22